Heartflow, Inc. 2025 Annual Report (10-K) Summary
Business Context and Reporting Period
This summary covers Heartflow, Inc.'s (HTFL) Annual Report on Form 10-K for the fiscal year ended December 31, 2025. Heartflow is a commercial-stage medical technology company providing AI-powered software to diagnose and manage coronary artery disease (CAD) non-invasively. The company completed its Initial Public Offering (IPO) on August 11, 2025, listing on the Nasdaq Global Select Market. As of year-end, the Heartflow Platform had assessed over 600,000 patients cumulatively, with 219,000 patients assessed in 2025 alone.
Key Financial Metrics
| Metric | 2025 | 2024 | Change |
|---|---|---|---|
| Revenue | $176.0 million | $125.8 million | +40% |
| Gross Profit | $135.2 million | $94.4 million | +43% |
| Gross Margin | 77% | 75% | +200 bps |
| Net Loss | $(116.8) million | $(96.4) million | +21% (wider loss) |
| Operating Loss | $(64.1) million | $(61.2) million | +5% |
| Cash & Investments | $280.2 million | $51.4 million | Significant increase |
| Accumulated Deficit | $(1.1) billion | $(971.0) million | N/A |
Revenue Composition: Heartflow FFR CT Analysis represented 98% of total revenue. Heartflow Plaque Analysis remains in early commercialization stages. Revenue cases increased 47% year-over-year to 198,340 (sum of quarterly cases), partially offset by a reduction in average sales price due to a higher mix of clinic-based accounts and volume rebates.
Material Changes vs. Prior Period
- Capital Structure Transformation: The company completed its IPO in August 2025, raising approximately $332.4 million in net proceeds. Concurrently, all outstanding redeemable convertible preferred stock and $98.3 million in 2025 Convertible Notes converted to common stock.
- Debt Elimination: The company fully repaid and terminated its 2024 Term Loan (aggregate principal of $60.1 million) in August 2025 using IPO proceeds. Consequently, interest expense decreased 48% to $9.6 million.
- Non-Cash Charges: Net loss widened primarily due to a $43.9 million non-cash charge related to the change in fair value of common stock warrant liability and a $6.4 million loss on extinguishment of debt.
- Expense Growth: Research and Development (R&D) expenses increased 49% to $64.9 million, driven by headcount growth and clinical trial investments. Selling, General, and Administrative (SG&A) expenses increased 20% to $134.3 million, reflecting public company costs and sales expansion.
Guidance, Outlook, and Risks
Outlook and Strategy: Management expects to continue incurring losses as it scales commercial operations and invests in R&D. Key growth drivers include expanding the installed base of accounts (1,465 as of Dec 31, 2025), increasing utilization at existing accounts, and broadening adoption of Heartflow Plaque Analysis following the establishment of a Category I CPT code (effective Jan 1, 2026). The company plans to launch Heartflow PCI Navigator in Q2 2026.
Material Risks and Contingencies:
- Government Investigation: In October 2025, the company received Civil Investigative Demands (CID) from the U.S. Department of Justice regarding financial arrangements with providers and sales/marketing activities under the Anti-Kickback Statute and False Claims Act. The outcome is uncertain and could materially impact the business.
- Reimbursement Risk: Revenue is heavily dependent on third-party payor coverage. A proposed 2026 Medicare rule could reduce reimbursement rates for FFR CT Analysis by up to 15%.
- Product Concentration: 98% of revenue is derived from a single product (FFR CT Analysis). Failure to commercialize Plaque Analysis or future products would limit growth.
- Profitability: The company has an accumulated deficit of $1.1 billion and expects to incur substantial losses in the foreseeable future.
Investor Verification Checklist
- Investigation Status: Monitor updates regarding the DOJ investigation into sales and marketing practices and potential financial penalties.
- Reimbursement Rates: Verify the finalization of the 2026 Medicare OPPS rule and its impact on FFR CT Analysis reimbursement rates.
- Plaque Analysis Adoption: Track the commercial uptake of Heartflow Plaque Analysis following the Jan 1, 2026, CPT code implementation and Medicare coverage expansion.
- Cash Burn Rate: Assess the runway provided by the $280.2 million cash position against the current operating loss trajectory and planned R&D investments.
- Customer Concentration: Review the concentration of revenue among top customers, as the loss of a few large systems could disproportionately impact results.